Initiated and organised entirely by the community of people living with and at risk for HIV, the second European HIV Prevention Summit brought together representatives of civil society, the pharmaceutical industry, researchers and academia in Brussels between 29 and 31 January. In addition to a thorough examination of PrEP (pre-exposure prophylaxis), the summit discussed the latest developments in the research fields of vaccines, rectal and vaginal microbicides and antibodies and their utility in HIV prevention.
03 February 2016 | EATG
It isn’t too out of the ordinary for Gates Foundation grant awards to soar into the eight- and even nine-figure range. So, its $20 million grant to Moderna Therapeutics to support its continuing development of a novel but promising HIV prevention therapy isn’t particularly extraordinary. But what is unusual...is that the total potential commitment from the foundation could reach upwards of $100 million—around 70 percent of the Gates Foundation’s HIV/AIDS grants for all of last year.
27 January 2016 | Inside Philanthropy
The European Commission has granted over 22 million Euros to the European HIV Vaccine Alliance (EHVA) to develop a multidisciplinary platform to evaluate novel preventive and therapeutic vaccines. The grant is supplemented with additional 6 million Euros from the Swiss government for the Swiss project partners.
27 January 2016 | Eurekalert Inf Dis
Human trials of more than 100 different AIDS vaccines have taken place since researchers proved in 1984 that HIV caused the disease. Robert Gallo, whose U.S. National Cancer Institute laboratory published the four landmark papers in Science that convinced the world of the link between this recently discovered retrovirus and the growing epidemic, has closely monitored—and often sharply critiqued—the AIDS vaccine search since it began. But Gallo, who now runs the Institute of Human Virology (IHV) in Baltimore, Maryland, has always been a spectator—until today.
14 October 2015 | Science Insider
HIV Prevention Research & Development Funding Trends 2000–2014: Investment Priorities To Fund Innovation In An Evolving Global Health And Development Landscape is the 11th annual report by the Working Group, a collaboration among AVAC, UNAIDS, and the International AIDS Vaccine Initiative (IAVI). The report summarizes investment in HIV prevention research across eight prevention options, as well as HSV-2 vaccine and HIV cure and therapeutic vaccine R&D.
19 July 2015 | AVAC
The massive challenge of finding an HIV vaccine has unleashed stunning creativity in laboratories all over the world. While we work toward the long-term goal of a vaccine, we are also pulling in partners from many sectors to improve prevention, treatment, and access to options in the short term.
13 July 2015 | Devex
An experimental Johnson & Johnson vaccine completely prevented HIV infection in half of monkeys that got the shot and then were exposed to high doses of an aggressive virus, results that spurred the company to test the vaccine in people, academic and company researchers said on Thursday.
03 July 2015 | Reuters
A research team led by Weill Cornell Medical College scientists has discovered a way to limit replication of the most common form of HIV at a key moment when the infection is just starting to develop. The study, published June 25 in Nature Communications, has shed light on a potential new element of human immunity against HIV-1 and could provide a powerful new strategy — perhaps as part of an HIV vaccine — to limit the severity of the disease.
26 June 2015 | Weill Cornell Medical College
A trio of studies being published today in the journals Science and Cell describes advances toward the development of an HIV vaccine. The three study teams all demonstrated techniques for stimulating animal cells to produce antibodies that either could stop HIV from infecting human cells in the laboratory or had the potential to evolve into such antibodies. Each of the research teams received funding from the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health.
19 June 2015 | Eurekalert Medicine & Health
Scientists have thought for some time that multiple immunizations, each tailored to specific stages of the immune response, could be used to generate a special class of HIV-fighting antibodies, so-called broadly neutralizing antibodies. New findings provide the first evidence supporting this approach.
19 June 2015 | Science Daily